PMID
Cmpds
Data
Article Title
Organization
25
Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.

The University of Newcastle
33
Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.

Abbott Laboratories
60
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.

Abbott Laboratories
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH

Jagiellonian University Medical College
42
Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics.

Huazhong University of Science and Technology
17
The discovery of quinoline based single-ligand human H

Glaxosmithkline
31
Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples.

University of Kansas
26
Identification of Ligand Binding Hot Spots of the Histamine H

Vrije Universiteit Amsterdam
20
Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.

Florida A&M University
20
Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.

Florida A&M University
18
Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.

Florida A&M University
28
Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.

Shanghai Institute of Materia Medica
30
Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.

University of Regensburg
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.

Jagiellonian University Medical College
6
Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.

The Alexander Shulgin Research Institute
24
2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.

Friedrich-Alexander-Universit£T Erlangen-N£Rnberg
27
Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.

Huazhong University of Science and Technology
5
Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.

Janssen Research and Development
10
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

Novartis Institutes For Biomedical Research
6
CNS drug design: balancing physicochemical properties for optimal brain exposure.

Eli Lilly
10
3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.

Teva Global R & D.
52
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.

Jagiellonian University Collegium Medicum
11
Further evaluation of the tropane analogs of haloperidol.

Florida A&M University
40
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).

Glaxosmithkline
43
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.

University of Siena
38
Loratadine and analogues: discovery and preliminary structure-activity relationship of inhibitors of the amino acid transporter B(0)AT2.

Max Planck Institute of Psychiatry
105
Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia.

Adamed
34
Identification of a new selective dopamine D4 receptor ligand.

Florida A&M University
23
Antagonists of the kappa opioid receptor.

The Scripps Research Institute
38
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.

Intra-Cellular Therapies
7
Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.

United Arab Emirates University
6
Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics.

Huazhong University of Science and Technology
8
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.

University of Missouri
3
Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.

Amgen
26
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.

Glaxosmithkline
16
The discovery of the benzazepine class of histamine H3 receptor antagonists.

Glaxosmithkline
1
Synthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1).

National Institute of Mental Health
5
Polypharmacology - foe or friend?

F. Hoffmann-La Roche
1
Discovery ofβ2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.

University of Dundee
3
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.

Virginia Commonwealth University
22
N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes ass receptor ligands with potential neuroprotective effects.

The University of Sydney
47
Discovery of ML314, a Brain Penetrant Non-Peptidicβ-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.

Sanford-Burnham Medical Research Institute
2
Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.

Columbia University Medical Center
3
Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.

Dalhousie University
2
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.

Ucl School of Pharmacy
2
Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).

Sanofi Us
18
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.

Institute of Organic Synthesis
17
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.

University of Siena
14
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.

Broad Institute of Mit and Harvard
12
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.

Huazhong University of Science and Technology
5
A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.

Griffin Discoveries
2
Bodilisant-a novel fluorescent, highly affine histamine h3 receptor ligand.

Goethe University
23
Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.

Vrije Universiteit Amsterdam
4
2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.

Janssen-Cilag
3
Optical isomers of the H1 antihistamine terfenadine: synthesis and activity

TBA
15
Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.

University of Regensburg
14
Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.

Glaxosmithkline
3
Linking agonist binding to histamine H1 receptor activation.

Vrije Universiteit Amsterdam
9
Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.

University of Regensburg
27
Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.

University of Regensburg
25
Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.

Johnson & Johnson Pharmaceutical Research & Development
15
N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.

University of Regensburg
60
Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.

Vrije Universiteit Amsterdam
82
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.

Glaxosmithkline
12
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.

Smithkline Beecham Pharmaceuticals
1
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.

Vrije Universiteit
48
Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.

Abbott Laboratories
21
Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.

Janssen-Cilag
21
Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.

Janssen-Cilag
53
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.

Abbott Laboratories
23
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.

AstraZeneca
30
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: optimising in vivo clearance.

AstraZeneca
12
Novel azulene derivatives for the treatment of erectile dysfunction.

Friedrich-Alexander University
29
As(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).

The University of Sydney
38
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

H. Lundbeck
12
From a4ß2 Nicotinic Ligands to the Discovery of s1 Receptor Ligands: Pharmacophore Analysis and Rational Design.

TBA
25
Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.

Sanford-Burnham Medical Research Institute
6
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT6 receptor antagonists.

Suven Life Sciences
37
Chemokine receptor antagonists.

National Heart and Lung Institute
40
The discovery of CCR3/H1 dual antagonists with reduced hERG risk.

AstraZeneca
9
Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.

University of Oxford
3
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

National Institute of Biological Sciences
52
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.

AstraZeneca
28
Histamine H3 receptor as a drug discovery target.

TBA
17
Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.

Glaxosmithkline
9
Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.

Cephalon
23
Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.

Florida A&M University
50
2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.

Pfizer
4
Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.

National Institute of Mental Health
23
Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.

National Institute of Mental Health
39
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela

Pfizer
49
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.

ASKA Pharmaceutical Co
34
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.

H. Lundbeck
19
Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.

Meiji Seika Kaisha
38
Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists.

Argenta Discovery
28
Novel benzothiophene H1-antihistamines for the treatment of insomnia.

Neurocrine Biosciences
1
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Hunter College and The Graduate Center of The City University of New York
9
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.

Veterans Affairs Medical Center
14
Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.

Johann Wolfgang Goethe Universit£T
35
Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.

University of Regensburg
17
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.

Tom'S of Maine
6
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.

Purdue University
7
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

The Johns Hopkins University School of Medicine
2
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.

Abbott Laboratories
60
In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series.

Abbott Laboratories
27
Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration.

F. Hoffmann-La Roche
35
Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.

F. Hoffmann-La Roche
6
4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.

Glaxosmithkline
3
Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism.

Janssen-Cilag
10
Novel piperazines: potent melanocortin-4 receptor antagonists with anxiolytic-like activity.

Taisho Pharmaceutical
17
(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.

Mitsubishi Pharma
95
Designed multiple ligands. An emerging drug discovery paradigm.

Organon Laboratories
5
Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.

Johnson & Johnson Pharmaceutical Research & Development
32
Selective optimization of side activities: another way for drug discovery.

Prestwick Chemical
43
Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.

Freie Universit£T Berlin
7
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.

Aventis Pharmaceuticals
20
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.

University of Siena
4
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).

Purdue University
22
Influence of bulky substituents on histamine h(3) receptor agonist/antagonist properties.

Freie Universit£T Berlin
24
Current and novel approaches to the drug treatment of schizophrenia.

Merck Sharp and Dohme Research Laboratories
5
N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.

Eli Lilly
48
From hit to lead. Analyzing structure-profile relationships.

Universities of Lille
7
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.

Universidad De Valencia
10
Studies on quinazolines and 1,2,4-benzothiadiazine 1,1-dioxides. 8.1, 2 synthesis and pharmacological evaluation of tricyclic fused quinazolines and 1,2,4-benzothiadiazine 1,1-dioxides as potential alpha1-adrenoceptor antagonists.

National Taiwan University
12
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.

Cooperation Pharmaceutique Francaise
4
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.

Wyeth-Ayerst Research
17
Synthesis and antihistaminic activity of some thiazolidin-4-ones.

University of Naples Federico II
21
Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.

Kyowa Hakko Kogyo
33
Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists.

Centre De Recherches De Vitry Alfortville Rh£Ne-Poulenc Rorer
55
Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents.

TBA
31
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.

TBA
9
(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.

Virginia Commonwealth University
26
Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity

TBA
16
1,1-diphenyl-3-dialkylamino-1-silacyclopentane derivatives: A new class of potent and selective 5-HT2A antagonists

TBA
24
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

University of Siena
12
Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.

Florida A&M University
23
Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.

Florida A&M University
33
Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.

Griffin Discoveries
21
Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H¿?-antihistamines for insomnia.

Neurocrine Biosciences
21
Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.

Cephalon
12
Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.

Cephalon
21
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.

Vu University Amsterdam
23
Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).

Pfizer
14
N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.

The University of Sydney
5
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.

Neurocrine Biosciences
24
Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.

Chemical Diversity Research Institute
6
Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.

The University of Sydney
17
N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands.

Jagiellonian University Medical College
21
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.

Dainippon Sumitomo Pharma
38
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.

Glaxosmithkline
25
Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.

Neurocrine Biosciences
10
Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.

The University of Sydney
37
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.

Glaxosmithkline
39
Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity fora(1)-adrenoceptors.

University of Copenhagen
18
Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.

National Institute of Mental Health
1
Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical and Public Health Institute
16
Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.

Meiji Seika Kaisha
64
Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.

Evotec (Uk)
21
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.

Università
36
Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.

Johnson & Johnson Pharmaceutical Research & Development
13
Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.

Meiji Seika Kaisha
27
The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.

Neurocrine Biosciences
27
Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.

Neurocrine Biosciences
2
The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.

Glaxosmithkline
58
Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.

F. Hoffmann-La Roche
5
9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.

Virginia Commonwealth University
11
1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.

Glaxosmithkline
29
Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.

Chemical Diversity Research Institute
33
2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.

Johann Wolfgang Goethe University
13
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.

University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and The Informatics Institute of Umdnj
29
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.

Arena Pharmaceuticals
12
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.

The Schering Plough Research Institute
20
Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.

Tsukuba Research Institute
25
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.

Neurocrine Biosciences
8
Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.

Neurocrine Biosciences
19
Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.

Tsukuba Research Institute
22
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.

Dainippon Sumitomo Phrama.
6
Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.

Tsukuba Research Institute
15
The Role of Receptor Binding in Drug Discovery

TBA
38
Use of CoMFA in validating the conformation used in designing 4-(1
H-benzimidazole-2-carbonyl)piperidines with H
1/NK
1 receptor antagonist activity

TBA
4
The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053)

TBA
7
5-O-Carboxymethyl piperazide derivatives of serotonin: a new class of potent and selective 5-HT
1D receptor agonists

TBA
5
The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D
4 (LTD
4)/platelet activating factor (PAF) receptor antagonists.

TBA
20
Dual antagonists of platelet activating factor and histamine. 2. pyridine ring substitution of N-acetyl-4-(8-chloro-5,6-dihydro-11
H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines

TBA
21
Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.

Institute of Nuclear Chemistry Johannes Gutenberg-University Mainz
20
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.

University of Siena
19
Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Tsukuba Research Institute
39
Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Tsukuba Research Institute
27
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.

Merck Research Laboratories
1
Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.

National Institute of Mental Health
29
Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.

Tsukuba Research Institute
26
Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.

Amgen
35
Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

Tsukuba Research Institute
16
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.

Florida A&M University
19
Semi-Synthesis of Dimeric Cannabidiol Derivatives and Evaluation of their Affinity at Neurological Targets.

University of South Carolina
1
Development of Squaramides as Allosteric Modulators of the CB1 Receptor: Synthesis, Computational Studies, Biological Characterization, and Effects against Cocaine-Induced Behavioral Sensitization and Reinstatement in Rats.

Research Triangle Institute
22
Probing the Histamine H1 Receptor Binding Site to Explore Ligand Binding Kinetics.

Vrije Universiteit Amsterdam
39
Structure activity relationships of 5-HT2B and 5-HT2C serotonin receptor antagonists: N6, C2 and 5'-Modified (N)-methanocarba-adenosine derivatives.

National Institute of Diabetes and Digestive and Kidney Diseases
6
From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.

F. Hoffmann-La Roche
30
Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach.

F. Hoffmann-La Roche
48
Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development.

Japan Tobacco
46
Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.

Pfizer
39
Natural Product-Inspired Dopamine Receptor Ligands.

City University of New York
29
WLB-87848, a Selective σ1 Receptor Agonist, with an Unusually Positioned NH Group as Positive Ionizable Moiety and Showing Neuroprotective Activity.

Welab Barcelona
5
Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.

National Institute of Mental Health
1
Discovery and

Small Pharma.
32
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.

Glaxosmithkline
21
Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents - Design, synthesis, structural studies and pharmacological profiling.

Medical University of Lublin
23
Dual Piperidine-Based Histamine H

Jagiellonian University Medical College
25
Novel sigma receptor ligands: synthesis and biological profile.

University of Catania
32
Targeting σ

The University of Texas At Austin
47
Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.

Galapagos
22
Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y

National Institute of Diabetes and Digestive and Kidney Diseases
10
New aryl-/heteroarylpiperazine derivatives of 1,7-dimethyl-8,9-diphenyl-4-azatricyclo[5.2.1.0

Medical University of Warsaw
12
What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.

University of Illinois At Chicago
24
Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.

High Point University
62
Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor.

Taisho Pharmaceutical
18
Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.

Hokkaido University
25
Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y

National Institute of Diabetes and Digestive and Kidney Diseases
63
Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H

University of Nottingham Biodiscovery Institute
1
Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.

University of Kansas
30
Synthesis and Biological Characterization of a Series of 2-Sulfonamidebenzamides as Allosteric Modulators of MrgX1.

University of Nebraska Medical Center
2
Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.

Florida A&M University
2
Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.

Columbia University College of Physicians and Surgeons
45
Abolishing Dopamine D

University of Regensburg
2
Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.

Columbia University College of Physicians and Surgeons
32
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.

The Schering Plough Research Institute
11
Synthesis of potent and selective serotonin 5-HT1B receptor ligands.

Columbia University College of Physicians and Surgeons
50
6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.

7Tm Pharma
26
Design and synthesis of new potent 5-HT

Cracow University of Technology
2
Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700.

H. Lundbeck
36
Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.

Janssen-Cilag
16
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.

Johnson & Johnson Pharmaceutical Research & Development
1
Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification.

Roche Palo Alto
102
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.

Beijing Normal University
8
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.

Guizhou Medical University
20
Synthesis and structure-activity relationships of piperidinylpyrrolopyridine derivatives as potent and selective H1 antagonists.

RhôNe-Poulenc Rorer
8
5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.

Ucb Pharma
24
2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.

Novo Nordisk
51
Synthesis and structure-activity relationships of novel histamine H1 antagonists: indolylpiperidinyl benzoic acid derivatives.

RhôNe-Poulenc Rorer
13
A Versatile Sub-Nanomolar Fluorescent Ligand Enables NanoBRET Binding Studies and Single-Molecule Microscopy at the Histamine H

University of Regensburg
13
Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.

Ucb Pharma
10
Discovery of Small-Molecule CD33 Pre-mRNA Splicing Modulators.

Pfizer
16
Adenosine A

Heinrich Heine University Duesseldorf
27
Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT

Jagiellonian University Medical College
22
Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.

Janssen-Cilag
11
5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.

Ucb Pharma
100
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.

Abbott Laboratories
52
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.

Bristol Myers Squibb
28
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.

Huazhong University of Science and Technology
53
Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H

University of Regensburg
36
Structure-Activity Relationship of Heterocyclic P2Y

National Institute of Diabetes and Digestive and Kidney Diseases
26
A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.

Abbott Laboratories
20
Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine.

The Schering Plough Research Institute
14
Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.

Hokkaido University
23
Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H

Zhejiang University
21
Structural modifications in the distal, regulatory region of histamine H

Jagiellonian University Medical College
19
Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics.

Jiangsu Ocean University
45
Synthesis and evaluation of potent pyrrolidine H(3) antagonists.

Abbott Laboratories
42
Isoquinolinone derivatives as potent CNS multi-receptor D

Jiangsu Ocean University
12
Synthesis and pharmacological evaluation of 6-piperidino- and 6-piperazinoalkyl-2(3H)-benzothiazolones as mixed sigma/5-HT(1A) ligands.

Université
23
Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.

Pharmazeutisches Institut Der UniversitäT Freiburg
27
Synthesis and biological evaluation of novel antipsychotic trans-4-(2-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)ethyl)cyclohexan-1-amine derivatives targeting dopamine/serotonin receptor subtypes.

Shanghai Institute of Pharmaceutical Industry
13
Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs.

Polish Academy of Sciences
26
Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H

Pfizer
11
Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.

Columbia University College of Physicians and Surgeons
22
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.

University of Chinese Academy of Sciences
1
Isolation and Synthesis of Veranamine, an Antidepressant Lead from the Marine Sponge

University of Mississippi
19
UR-DEBa242: A Py-5-Labeled Fluorescent Multipurpose Probe for Investigations on the Histamine H

University of Regensburg
19
Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H

Jagiellonian University Medical College
1
De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.

Synaptic Pharmaceutical
16
Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.

Merck
10
Conformationally-restricted ligands for the histamine H1 receptor.

University of Bath
15
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.

National Institute of Diabetes and Digestive and Kidney Diseases
32
Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.

The R. W. Johnson Pharmaceutical Research Institute
18
Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H

China Pharmaceutical University
112
Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D

National Institute of Neurological Disorders and Stroke
4
Rasagiline derivatives combined with histamine H

Heinrich Heine University D£Sseldorf
22
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.

Knoll Pharmaceuticals
50
Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D

University of Pennsylvania
45
Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D

University of North Carolina at Chapel Hill
16
New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.

University of GöTeborg
15
Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.

Schering-Plough Research Institute
37
Design and in Vivo Characterization of A

Medical College of Wisconsin
24
Route to Prolonged Residence Time at the Histamine H

Vu University Amsterdam
31
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.

Rti International
13
Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo.

Schering-Plough Research Institute
28
Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.

Synaptic Pharmaceutical
3
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.

University of Florida
17
Synthesis and evaluation of histamine H

Jiangsu Marine Resources Development Research Institute
9
Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.

University of Groningen
25
3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT

University of Minnesota Twin Cities
25
Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.

Yamanouchi Pharmaceutical
47
Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity.

Freie UniversitäT Berlin
13
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.

Solvay Duphar
15
Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1.

Kyowa Hakko Kogyo
8
A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist.

Schering-Plough Research Institute
4
(Piperidinylalkoxy)chromones: novel antihistamines with additional antagonistic activity against leukotriene D4.

Vrije Universiteit
25
Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.

Drug Discovery Laboratory
51
Histamine H4 receptor agonists.

University of Regensburg
13
Design, synthesis, and docking studies of novel benzopyrone derivatives as H(1)-antihistaminic agents.

Cairo University
52
Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.

Vrije Universiteit Amsterdam
12
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.

Solvay Pharma
2
Side-chain modified analogues of histaprodifen: asymmetric synthesis and histamine H1-receptor activity.

Universit£T Regensburg
22
N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.

Vrije Universiteit Amsterdam
35
Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.

Johannes Gutenberg-University of Mainz
15
Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.

Freie Universit£T Berlin
51
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.

Huazhong University of Science and Technology
15
Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.

Pfizer
8
Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.

Texas Tech University Health Sciences Center
2
In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.

TBA
34
Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.

Shanghai Institute of Materia Medica
28
Synthesis and activity of di- or trisubstituted N-(phenoxyalkyl)- or N-{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous system.

Jagiellonian University Medical College
24
Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.

University of Chinese Academy of Sciences
24
Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.

University of Texas At Austin
6
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.

A.H. Robins
49
Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets.

University of California San Francisco
49
Identification and biological evaluation of thiazole-based inverse agonists of RORγt.

Phenex Pharmaceuticals
37
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.

Xinjiang Technical Institute of Physics and Chemistry
22
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.

Northwestern University
25
Return of D

University of Nebraska Medical Center
15
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.

Pfizer
9
Optical isomers of rocastine and close analogues: synthesis and H1 antihistaminic activity of its enantiomers and their structural relationship to the classical antihistamines.

A.H. Robins
26
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.

Schering-Plough
128
SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION

Genentech
17
STK19 inhibitors for treatment of cancer

Trustees of Boston University
37
LDHA activity inhibitors

Arctic Pharma
11
Quinazoline compound for EGFR inhibition

Medshine Discovery
59
Spirocyclic compounds

Recurium Ip Holdings
35
Biaryltriazole inhibitors of macrophage migration inhibitory factor

Yale University
52
Heterocyclic inhibitors of monocarboxylate transporter

The Scripps Research Institute
107
Heterocyclic compounds and uses thereof

Infinity Pharmaceuticals
135
Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors

Ctxt
3
Urea derivatives and uses thereof

Kala Pharmaceuticals
18
Methods of use of cyclopamine analogs

Infinity Pharmaceuticals
3
Inhibitors of PTP4A3 for the treatment of cancer

University of Virginia Patent Foundation
170
Compounds and compositions for inhibiting the activity of SHP2

Novartis
60
Tricyclic heterocyclic compounds useful as inhibitors of TNF

Bristol Myers Squibb
3
Fucosidase inhibitors

Horizon Orphan
63
Heteroaromatic compounds as BTK inhibitors

Boehringer Ingelheim International
2
Arylpiperazine derivatives and methods of utilizing same

Reviva Pharmaceuticals
130
Urea and amide derivatives of aminoalkylpiperazines and use thereof

Southern Research Institute
6
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

Ogeda
1
Morphinan derivative

University of Tsukuba
54
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2

Novartis
147
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives

Idorsia Pharmaceuticals
25
Inhibitors of beta-secretase

Vitae Pharmaceuticals
2
Compounds as rearranged during transfection (RET) inhibitors

Glaxosmithkline
303
TGF-β inhibitors

Rigel Pharmaceuticals
22
Bicyclic heterocyclic compounds as PDE2 inhibitors

Merck Sharp & Dohme
129
CXCR7 antagonists

Chemocentryx
35
Morphan and morphinan analogues, and methods of use

Alkermes Pharma Ireland
15
2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists

Merck Sharp & Dohme
18
Substituted aminopyrimidine compounds and methods of use

Calitor Sciences
20
Synthesis, a-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl-7-methylbenzimidazoles.

Universiti Teknologi Mara (Uitm), Puncak Alam Campus
10
Chymase inhibitors

Boehringer Ingelheim International
89
Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer

Human Biomolecular Research Institute
5
Inhibitory effect on soybean lipoxygenase and docking studies of some secondary metabolites, isolated from Origanum vulgare L. ssp. hirtum.

University of Athens
3
Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists.

University of Melbourne
14
Method of treating COVID-19

Pfizer
3
Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs.

University of California San Francisco
13
Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase.

Merck Research Laboratories
15
Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase.

The Scripps Research Institute
2
Identification of RIP1 kinase as a specific cellular target of necrostatins.

Tufts University
6
Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Eisai
33
Correlating solution binding and ESI-MS stabilities by incorporating solvation effects in a confined cucurbit[8]uril system.

University of Cambridge
10
Rigid duplex alpha-cyclodextrin reversibly connected with disulfide bonds. Synthesis and inclusion complexes.

Institute of Organic Chemistry and Biochemistry As Cr
15
Thermodynamics of the molecular and chiral recognition of cycloalkanols and camphor by modified beta-cyclodextrins possessing simple aromatic tethers.

Nankai University
8
Host properties of cyclodextrins towards anion constituents of antigenic determinants. A thermodynamic study in water and in N,N-dimethylformamide

University of Surrey
10
Thermodynamics of molecular recognition by cyclodextrins. 1. Calorimetric titration of inclusion complexation of naphthalenesulfonates with .alpha.-, .beta.-, and .gamma.-cyclodextrins: enthalpy-entropy compensation

Himeji Institute of Technology
92
Chiral Recognition Thermodynamics of β-Cyclodextrin: The Thermodynamic Origin of Enantioselectivity and the Enthalpy-Entropy Compensation Effect

Japan Science and Technology Agency
18
Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.

Virginia Commonwealth University
19
Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.

Ono Pharmaceutical
70
Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.

Vernalis (R&D)
17
Carbonic anhydrase inhibitors. The nematode alpha-carbonic anhydrase of Caenorhabditis elegans CAH-4b is highly inhibited by 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides.

Istanbul University
29
Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).

University of Manchester
17
Biarylether amide quinolines as liver X receptor agonists.

Wyeth Research
17
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.

Duquesne University
10
Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.

Cnrs
31
Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

Pfizer
37
Compounds binding to the S2-S3 pockets of thrombin.

University of Kalmar
14
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.

Bristol Myers Squibb
20
Chalcones: a valid scaffold for monoamine oxidases inhibitors.

Sapienza University of Rome
14
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.

Universita Del Piemonte Orientale
48
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.

Nerviano Medical Sciences
24
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.

Abbott Laboratories
12
Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.

Gsk
35
Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors.

University of Southern California
5
Design, Synthesis, and Evaluation of Tricyclic, Conformationally Constrained Small-Molecule Mimetics of Second Mitochondria-Derived Activator of Caspases.

Shanghai Institute of Organic Chemistry
17
The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.

Gsk
7
The molecular interactions of buspirone analogues with the serotonin transporter.

National Medicines Institute
25
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.

Sunesis Pharmaceuticals
30
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

AstraZeneca
9
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.

Irbm/Merck Research Laboratories
1
Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Methylgene
23
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Nih
16
Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics.

University of Michigan
17
Syntheses and anticholinesterase activities of (3aS)-N1, N8-bisnorphenserine, (3aS)-N1,N8-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine.

University of North Carolina at Chapel Hill
0
Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1.

University of Otago
2
Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors.

Burnham Institute For Medical Research